Cargando…

A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients

Hydroxyurea and low dose thalidomide are low-cost, easily accessible Hb F inducing agents that have been found to decrease transfusion dependency among transfusion-dependent thalassemia patients. However, these drugs have not much been explored in a randomized controlled setting. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharjee, Urmimala, Khadwal, Alka, Shafiq, Nusrat, Lad, Deepesh, Sharma, Prashant, Das, Reena, Shukla, Prateek, Jain, Arihant, Prakash, Gaurav, Malhotra, Pankaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809516/ https://www.ncbi.nlm.nih.gov/pubmed/36620489 http://dx.doi.org/10.1007/s12288-022-01620-3

Ejemplares similares

Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)
por: Singh, Charanpreet, et al.
Publicado: (2022)

Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation
por: Khaire, Niranjan S., et al.
Publicado: (2021)

Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia
por: Ansari, Saqib H., et al.
Publicado: (2022)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients
por: Chopra, Madhu, et al.
Publicado: (2022)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India
por: Khaire, Niranjan S., et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020)

Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients
por: Bordbar, Mohammad Reza, et al.
Publicado: (2014)

Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance
por: Nair, Ashwin, et al.
Publicado: (2023)

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
por: Jain, Arihant, et al.
Publicado: (2020)

Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021)

Challenges in transfusion and the role of Thalidomide in E‐β‐Thalassemia—A case report
por: Javed, Rizwan, et al.
Publicado: (2020)

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis
por: Hatamleh, Modather I, et al.
Publicado: (2023)

Cytopathological Diagnosis of an Unusual Cause of Malignant Hydrocele
por: Jain, Ankur, et al.
Publicado: (2016)

Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study
por: Li, Xinyu, et al.
Publicado: (2021)

Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial
por: Chen, Jiang-Ming, et al.
Publicado: (2021)

Variation in Adherence Measures to Imatinib Therapy
por: Yanamandra, Uday, et al.
Publicado: (2017)

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan
por: Akram, Sumera, et al.
Publicado: (2022)

Complications and management of coagulation disorders in leukemia patients
por: Lad, Deepesh, et al.
Publicado: (2017)

Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature
por: Bommannan, Karthik, et al.
Publicado: (2016)

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea
por: Zekavat, Omid Reza, et al.
Publicado: (2014)

Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia
por: Chen, Yaocheng, et al.
Publicado: (2020)

Thalidomide for Patients with β-Thalassemia: A Multicenter Experience
por: Yang, Kun, et al.
Publicado: (2020)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study
por: Ali, Zahid, et al.
Publicado: (2023)

Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea
por: Khavari, Maryam, et al.
Publicado: (2014)

Magnetic Resonance Imaging Quantification of the Liver Iron Burden and Volume Changes Following Treatment With Thalidomide in Patients With Transfusion-Dependent ß-Thalassemia
por: Che, Jinlian, et al.
Publicado: (2022)

Burden of caregiving and its impact in the patients of acute lymphoblastic leukemia
por: Kumari, Rina, et al.
Publicado: (2018)

Invasive Aspergillosis and Candidiasis in a Patient with Plasma Cell Myeloma
por: Khadwal, Alka, et al.
Publicado: (2023)

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
por: Lebensburger, Jeffrey D, et al.
Publicado: (2015)

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018)

Haploidentical Transplant in Radiosensitive Severe Combined Immunodeficiency Disease
por: Saini, Manpreet, et al.
Publicado: (2023)

Thalidomide-Induced Primary Amenorrhea in a Patient With HbE/Beta-Thalassemia
por: Singha, Arijit, et al.
Publicado: (2023)

In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
por: MAHDAVI, Mohammad Reza, et al.
Publicado: (2017)

Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea
por: Abolhasani Foroughi, Amin, et al.
Publicado: (2015)

Severe Cutaneous Adverse Reaction (SCAR): Clinical Pharmacologists’ Viewpoint
por: Shafiq, Nusrat, et al.
Publicado: (2022)

Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis
por: Lu, Yanfei, et al.
Publicado: (2022)

Pulmonary Functions in Transfusion-Dependent Thalassemia
por: Chandra, Jagdish, et al.
Publicado: (2022)

Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population
por: Taneja, Rashi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h9g3qlkh3k1v06tipm2ukm5mrm